Table 1.
Patient demographics and disease characteristics
| Characteristics | Remission (n = 1346) |
Active disease (n = 583) |
Post proctocolectomy (n = 42) |
|---|---|---|---|
| Demographics | |||
| Age (years), median (IQR)a | 44 (21) | 42 (21) | 45 (18) |
| Sex, n (%) | |||
| Male | 711 (52.8) | 327 (56.1) | 33 (78.6) |
| Female | 633 (47.0) | 255 (43.7) | 9 (21.4) |
| Missing | 2 (0.1) | 1 (0.2) | 0 |
| BMI, median (IQR)b | 21.7 (4.2) | 21.6 (4.7) | 20.9 (4.3) |
| Disease characteristics | |||
| Age at diagnosis (years), median (IQR)c | 33 (21) | 30 (19) | 34 (24) |
| Disease duration (years), median (IQR)d | 9.3 (11.0) | 9.0 (12.2) | 11.3 (13.4) |
| Disease extent, n (%) | |||
| Extensive colitis | 735 (54.6) | 291 (49.9) | 35 (83.3) |
| Left-sided colitis | 324 (24.1) | 172 (29.5) | 6 (14.3) |
| Proctitis | 245 (18.2) | 101 (17.3) | 0 |
| Right-sided colitis | 20 (1.5) | 4 (0.7) | 0 |
| Unknown | 18 (1.3) | 6 (1.0) | 1 (2.4) |
| Missing | 4 (0.3) | 9 (1.5) | 0 |
| Extraintestinal manifestations, n (%) | |||
| Peripheral arthropathy | 41 (3.0) | 18 (3.1) | 3 (7.1) |
| Erythema nodosum | 8 (0.6) | 4 (0.7) | 0 |
| Primary sclerosing cholangitis | 7 (0.5) | 2 (0.3) | 0 |
| Aphthous stomatitis | 6 (0.4) | 3 (0.5) | 0 |
| Pancreatitis | 6 (0.4) | 3 (0.5) | 0 |
| Pyoderma gangrenosum | 6 (0.4) | 2 (0.3) | 0 |
| Spine arthropathy | 5 (0.4) | 3 (0.5) | 1 (2.4) |
| Iritis | 1 (0.1) | 1 (0.2) | 0 |
| Ankylosing spondylitis | 1 (0.1) | 0 | 0 |
| Scleritis | 1 (0.1) | 0 | 0 |
| Other skin lesion | 31 (2.3) | 15 (2.6) | 0 |
| Missing | 0 | 1 (0.2) | 0 |
| Abdominal pain (NRS), median (IQR)e | 0 (1) | 1 (3) | 0 (3) |
| Current medication, n (%) | |||
| 5-ASA (oral) | 1154 (85.7) | 496 (85.1) | 12 (28.6) |
| Immunomodulators | 331 (24.6) | 135 (23.2) | 2 (4.8) |
| TNF-alpha inhibitors | 219 (16.3) | 124 (21.3) | 6 (14.3) |
| Systemic steroids (prednisolone) | 59 (4.4) | 39 (6.7) | 5 (11.9) |
| Calcineurin inhibitors | 16 (1.2) | 19 (3.3) | 0 |
| Tofacitinib | 15 (1.1) | 18 (3.1) | 1 (2.4) |
| Apheresis | 5 (0.4) | 1 (0.2) | 0 |
| Vedolizumab | 2 (0.1) | 3 (0.5) | 1 (2.4) |
5-ASA 5-aminosalicylic acid, BMI body mass index, IQR interquartile range, NRS numerical rating scale, TNF tumor necrosis factor
aRemission (n = 1344), Active disease (n = 583), Post proctocolectomy (n = 42)
bRemission (n = 1340), Active disease (n = 583), Post proctocolectomy (n = 42)
cRemission (n = 1288), Active disease (n = 564), Post proctocolectomy (n = 41)
dRemission (n = 1290), Active disease (n = 566), Post proctocolectomy (n = 41)
eRemission (n = 1343), Active disease (n = 583), Post proctocolectomy (n = 42)